Skip to main content
Premium Trial:

Request an Annual Quote

CellCarta Acquires Reveal Biosciences

NEW YORK – Montreal-based CellCarta, formerly known as Caprion-HistoGeneX, said on Wednesday that it has acquired artificial intelligence-based pathology firm Reveal Biosciences for an undisclosed amount.

CellCarta will use the acquisition to broaden its offering in AI-enabled multiomic data analysis services and applications.

San Diego-based Reveal's ImageDx image-analysis software combines machine learning with histopathology to turn tissue biology into actionable data.

The firm said that its pipeline architecture and biomarker-based training methods also allow development of scalable custom AI models for specific pathology endpoints, companion diagnostics, and predictive models combining multiomic data.

"Reveal's broad portfolio of automated digital assays target oncology, NASH, neuroscience, fibrosis, inflammation, and other therapeutic areas," Claire Weston, CEO and cofounder of Reveal, said in a statement. "We see great opportunity in combining these AI capabilities, with CellCarta driving towards better diagnoses and more meaningful clinical trials on a global scale."

"Reveal's exceptional AI and machine learning capabilities will support more objective tissue biomarker quantitation and will enable a broader and faster deployment of our histological services," Martin LeBlanc, CEO of CellCarta, said in a statement. "Acquiring this leading business is part of a game-changing strategy to expand our services to better support our global clients who are actively seeking more objective, reproducible, and scalable methods for tissue biomarker assessment."